Thomas F. Gajewski
· AbbVie Foundation ProfessorUniversity of Chicago · Immunology and Inflammation
Active 1956–2025
Academic metrics are sourced from OpenAlex and public funding records; values may differ from Google Scholar.
About
Thomas F. Gajewski is a Professor at the University of Chicago in the Department of Pathology. His research activities focus on immunotherapy and tumor microenvironment, with a particular emphasis on overcoming resistance to immune checkpoint inhibitors such as anti-PD1 therapy. His work involves studying the molecular and cellular mechanisms underlying anti-tumor immunity, including the roles of T cells, myeloid cells, and dendritic cells in cancer progression and treatment response. Gajewski's contributions include investigating the genetic and biochemical factors that influence immune responses in melanoma and other solid tumors. His research aims to enhance the efficacy of immunotherapies by understanding immune resistance mechanisms and developing strategies to modulate the tumor microenvironment. He has been involved in numerous NIH-funded projects as a Principal Investigator, exploring pathways such as STING, T cell regulation, and immune tolerance, and their implications for cancer therapy.
Research topics
- Medicine
- Internal medicine
- Oncology
- Cancer research
- Biology
- Gastroenterology
- Immunology
- Genetics
- Pathology
- Bioinformatics
Selected publications
Gastroenterology · 2020 · 368 citations
Senior authorCorrespondingJournal of Clinical Oncology · 2022 · 267 citations
PURPOSE: The combination of talimogene laherparepvec (T-VEC) and pembrolizumab previously demonstrated an acceptable safety profile and an encouraging complete response rate (CRR) in patients with advanced melanoma in a phase Ib study. We report the efficacy and safety from a phase III, randomized, double-blind, multicenter, international study of T-VEC plus pembrolizumab (T-VEC-pembrolizumab) versus placebo plus pembrolizumab (placebo-pembrolizumab) in patients with advanced melanoma. METHODS:…
Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma
Journal of Clinical Oncology · 2021 · 220 citations
PURPOSE: Combination of antiprogrammed cell death protein-1 (PD-1) plus anti-cytotoxic T-cell lymphocyte-4 (anti-CTLA-4) immunotherapy shows greater response rates (RRs) than anti-PD-1 antibody alone in melanoma, but RR after initial anti-PD-1 and programmed death ligand-1 (PD-L1) antibody progression awaits robust investigation. Anti-CTLA-4 antibody alone after anti-PD-1/L1 antibody progression has a historical RR of 13%. We report the results of the first prospective clinical trial evaluating…
Nature Cancer · 2022 · 90 citations
Clinical Cancer Research · 2020 · 70 citations
PURPOSE: Multisite stereotactic body radiotherapy followed by pembrolizumab (SBRT+P) has demonstrated safety in advanced solid tumors (ASTs). However, no studies have examined the relationships between irradiated tumor response, SBRT-induced tumor gene expression, and overall survival (OS). PATIENTS AND METHODS: Patients with AST received SBRT (30-50 Gy in 3-5 fractions) to two to four metastases followed by pembrolizumab (200 mg i.v. every 3 weeks). SBRT was prescribed to a maximum tumor volume…
Recent grants
NIH · $1.4M · 2006
NIH · $295k · 2004
NIH · $12.5M · 2014
Frequent coauthors
- 336 shared
Jason J. Luke
- 306 shared
Yuanyuan Zha
Second Military Medical University
- 254 shared
Theodore Karrison
University of Chicago
- 248 shared
Gini F. Fleming
- 248 shared
Mark J. Ratain
University of Chicago
- 235 shared
Linda Janisch
- 234 shared
Ralph R. Weichselbaum
University of Chicago
- 234 shared
Steven J. Chmura
University of Chicago
Similar researchers at University of Chicago
- Resume-aware match score
- Save to shortlist
- AI-drafted outreach
See your match with Thomas F. Gajewski
PhdFit ranks faculty by your research interests, methods, and publications — grounded in their actual work, not templates.
- Free to start
- No credit card
- 30-second signup